Preventing the onset of osteonecrosis of the jaw in patients with intravenous bisphosphonate medication
Romanian Journal of Stomatology · 2015
DOI: 10.37897/rjs.2015.2.11 ↗Abstract
Osteonecrosis of the jaw (ONJ) induced by treatment with bisphosphonates is an adverse effect at this class of drugs whose history in the treatment of osteoporosis and bone malignant neoplasm is not very long, the first cases being reported in 2003-2004. Unfortunately, progress on both the number of cases and their complexity is fulminating. Currently, any dentist should be familiar with the symptoms of the disease but also with the potential risk of onset as well as its prevention. In this paper we present a therapeutic protocol that includes the use of piezosurgery, laser therapy, autologous platelet concentrates (A-PRF) and antibiotic applicable in patients with osteoporosis or bone malignancies undergoing treatment with bisphosphonates intravenously so as to prevent the installation of ONJ.
EUVIMED